IDEXX Laboratories Inc（IDXX）財務資料IDXXIDEXX Laboratories Inc

IDEXX Laboratories, Inc. (IDXX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CAG Diagnostics recurring revenue, accounting for 80.1% of total sales, equivalent to $974.71M. Other significant revenue streams include IDEXX VetLab consumables and Reference laboratory diagnostic and consulting services. Understanding this composition is critical for investors evaluating how IDXX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, IDEXX Laboratories, Inc. maintains a gross margin of 63.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 33.43%, while the net margin is 27.82%. These profitability ratios, combined with a Return on Equity (ROE) of 74.21%, provide a clear picture of how effectively IDXX converts its operational activities into shareholder value.

In the context of the broader market, IDXX competes directly with industry leaders such as WAT and MDLN. With a market capitalization of $43.95B, it holds a significant position in the sector. When comparing efficiency, IDXX's gross margin of 63.71% stands against WAT's 29.79% and MDLN's 26.52%. Such benchmarking helps identify whether IDEXX Laboratories, Inc. is trading at a premium or discount relative to its financial performance.

IDEXX has demonstrated robust financial performance, with total revenue increasing to $1.216 billion in Q2 2026 and a net income of $338.4 million, reflecting a year-over-year growth in EPS of 18%.